Canadian Cancer Trials Group Bulletins

2015

Canadian Cancer Trials Group Bulletin

Canadian Cancer Trials Group

Canadian Cancer Trials Group Bulletin

18 Dec 2015

General

Kim Chi Awarded $500,000 from 3CTN
Dr. Kim Chi, Co-Chair of Canadian Cancer Trials Group's GU Site Committee and medical oncologist at BCCA Vancouver, has been awarded $500,000 from the 3CTN for support of an exciting new IND Program suite of trials in castrate resistant prostate cancer.

Read more ....

'

Single-Study Centres and DSMC Summary Reports
Trial-specific DSMC Summary Reports are now posted on trial websites. Single-study centres participating on these trials should download these reports and submit them to their Research Ethics Boards if required by local policy.

Read more ....

'

Canadian Cancer Trials Group Bulletin in 2016
The first Bulletin of 2016 will be sent on Friday, January 16.

Read more ....

'

Group Administrators Office

Canadian Cancer Trials Group Central Ops and Stats Office Holiday Closure
The Canadian Cancer Trials Group Central Ops and Stats Office will be closed with limited staff over the holidays. Web-based applications (i.e. MANGO, GCP) will be available. Please see the Canadian Cancer Trials Group website ... https://www.ctg.queensu.ca/public/holiday-closure-2015.

Read more ....

'

Office of Compliance and Oversight

Happy Holidays and Happy New Year!!!
The Canadian Cancer Trials Group's Central Operations and Statistics Office wishes everyone a very Merry Christmas, Happy Holidays, and Happy New Year.

Read more ....

'

Canadian Food and Drug Regulations Div. 5 Training Update
Additional grace period for completion of Canadian Food and Drug Regulations Division 5 Training drawing to a close.

Read more ....

'

Trial Management Group

Trial Activations
Two trials were recently centrally activated -- Canadian Cancer Trials Group MA.38 and NCIC MAC.19 (Alliance A011202).

Read more ....

'

You are receiving this Bulletin because of your involvement with the Canadian Cancer Trials Group. If you no longer wish to receive Canadian Cancer Trials Group Bulletins, please send an unsubscribe request by clicking here.

If you have any questions, comments or suggestions, please contact Canadian Cancer Trials Group Bulletin


Canadian Cancer Trials Group Bulletin

Canadian Cancer Trials Group

Canadian Cancer Trials Group Bulletin

04 Dec 2015

General

Recent Publications
There are a number of recent publications, including one related to Canadian Cancer Trials Group MA.5, another to PA.3, a third describing Canadian Cancer Trials Group GA.1 (TROG 0808), and the fourth reporting consensus guidelines for delineating organs at risk for head and neck radiotherapy.

Read more ....

'

Group Administrators Office

Canadian Cancer Trials Group Recognition Awards
The Central Operations and Statistics Office is seeking nominations for the 2016 Recognition Awards honouring individuals and teams who have contributed significantly to the mission and activities of the Group.

Read more ....

'

Trial Management Group

Trial Closed to Accrual
Canadian Cancer Trials Group CRC.6 (CALGB-80702) was closed to accrual on Friday, November 20, 2015. Final accrual was 2425 of which 233 patients were from Canada.

Read more ....

'

Trials Recently Permanently Closed
Eight trials, 4 led by the Canadian Cancer Trials Group and 4 intergroup-led trials that included Canadian Cancer Trials Group participation, are now complete, have been recently permanently closed, and no longer require action, including patient follow-up.

Read more ....

'

You are receiving this Bulletin because of your involvement with the Canadian Cancer Trials Group. If you no longer wish to receive Canadian Cancer Trials Group Bulletins, please send an unsubscribe request by clicking here.

If you have any questions, comments or suggestions, please contact Canadian Cancer Trials Group Bulletin


Canadian Cancer Trials Group Bulletin

Canadian Cancer Trials Group

Canadian Cancer Trials Group Bulletin

22 Nov 2015

General

Recent Publications
There are 4 recent publications, including the primary results of Canadian Cancer Trials Group IND.191 - A Phase II Study of AT9283 in Patients with Relapsed or Refractory Multiple Myeloma.

Read more ....

'

Trial Management Group

RIPPLE - Roll-Out of New Features and Screens
Next Friday, November 27, the Central Office RIPPLE Team will be rolling out several new features, including new screens and new reports. An updated User Guide will also be released.

Read more ....

'

You are receiving this Bulletin because of your involvement with the Canadian Cancer Trials Group. If you no longer wish to receive Canadian Cancer Trials Group Bulletins, please send an unsubscribe request by clicking here.

If you have any questions, comments or suggestions, please contact Canadian Cancer Trials Group Bulletin


Canadian Cancer Trials Group Bulletin

Canadian Cancer Trials Group

Canadian Cancer Trials Group Bulletin

20 Nov 2015

General

Recent Publications
There are 4 recent publications, including the primary results of Canadian Cancer Trials Group IND.191 - A Phase II Study of AT9283 in Patients with Relapsed or Refractory Multiple Myeloma.

Read more ....

'

Trial Management Group

RIPPLE - Roll-Out of New Features and Screens
Next Friday, November 27, the Central Office RIPPLE Team will be rolling out several new features, including new screens and new reports. An updated User Guide will also be released.

Read more ....

'

You are receiving this Bulletin because of your involvement with the Canadian Cancer Trials Group. If you no longer wish to receive Canadian Cancer Trials Group Bulletins, please send an unsubscribe request by clicking here.

If you have any questions, comments or suggestions, please contact Canadian Cancer Trials Group Bulletin


Canadian Cancer Trials Group Bulletin

Canadian Cancer Trials Group

Canadian Cancer Trials Group Bulletin

06 Nov 2015

General

Dr. Joseph Pater Recognized by CCRA
Dr. Joseph Pater, founding director of Canadian Cancer Trials Group, has been recognized by the Canadian Cancer Research Alliance (CCRA) for Outstanding Achievements in Cancer Research.

Read more ....

'

Recent Publication
Primary results of Canadian Cancer Trials Group MA.22 - A Phase I/II Study of Increasing Doses of Epirubicin and Docetaxel Plus Pegfilgrastim for Locally Advanced Or Inflammatory Breast Cancer - were recently published.

Read more ....

'

Dr. Ming Tsao Receives Award at WCLC
Dr. Ming Tsao, Chair of Canadian Cancer Trials Group's Correlative Sciences Tumour Biology Committee, was recently presented with the Mary J. Matthews Pathology/Translational Research Award at the 16th World Conference on Lung Cancer (WCLC).

Read more ....

'

It Starts With Me
A new website (www.itstartswithme.ca), developed by patients and caregivers and by people who work in clinical trials, provides information to the public about participating in clinical trials and aims to generate interest and awareness.

Read more ....

'

Group Administrators Office

Canadian Cancer Trials Group Recognition Awards
Canadian Cancer Trials Group's Central Operations and Statistics Office is seeking nominations for the 2016 Canadian Cancer Trials Group Recognition Awards honouring individuals and teams who have contributed significantly to the mission and activities of the Group.

Read more ....

'

Trial Management Group

Trial Closed to Accrual
Canadian Cancer Trials Group ALC.3 / SWOG 1203 was closed to further accrual on November 5, 2015.

Read more ....

'

You are receiving this Bulletin because of your involvement with the Canadian Cancer Trials Group. If you no longer wish to receive Canadian Cancer Trials Group Bulletins, please send an unsubscribe request by clicking here.

If you have any questions, comments or suggestions, please contact Canadian Cancer Trials Group Bulletin


Canadian Cancer Trials Group Bulletin

Canadian Cancer Trials Group

Canadian Cancer Trials Group Bulletin

23 Oct 2015

General

Recent Publications
There were three recent publications -- one related to Canadian Cancer Trials Group MA.22 and two others from the Early Breast Cancer Trialists' Collaborative Group (EBCTCG).

Read more ....

'

Canadian Cancer Trials Group SC.23 Results Highlighted at ASTRO
Results of Canadian Cancer Trials Group SC.23 that show that cancer patients with bone metastases undergoing radiation therapy for symptom control have a lower rate of pain flare with steroid use were recently highlighted at ASTRO.

Read more ....

'

Dr. Eva Grunfeld Vinyl Cafe Arthur Awardee
Dr. Eva Grunfeld was recently presented with an Arthur Award from Stuart McLean during the October 11, 2015 edition of CBC's The Vinyl Cafe.

Read more ....

'

Trial Management Group

Trials Closed to Accrual
Two trials were recently closed to accrual - Canadian Cancer Trials Group IND.215 and Canadian Cancer Trials Group MAC.15 (SWOG 1007) - after reaching their accrual targets.

Read more ....

'

You are receiving this Bulletin because of your involvement with the Canadian Cancer Trials Group. If you no longer wish to receive Canadian Cancer Trials Group Bulletins, please send an unsubscribe request by clicking here.

If you have any questions, comments or suggestions, please contact Canadian Cancer Trials Group Bulletin


Canadian Cancer Trials Group Bulletin

Canadian Cancer Trials Group

Canadian Cancer Trials Group Bulletin

09 Oct 2015

General

Recent Publications
There were two recent publications, including first results from the Canadian Cancer Trials Group MAC.12 (ECOG PACCT-1) TAILORx trial recently published in the New England Journal of Medicine. The other is related to Canadian Cancer Trials Group SC.20.

Read more ....

'

Group Administrators Office

Central Operations and Statistics Office Holiday Closure
The Canadian Cancer Trials Group Central Operations and Statistics Office will be closed for Thanksgiving on Monday, October 12. Regular business hours will resume on Tuesday, October 13 at 8:30 am EDT.

Read more ....

'

Stand Up to Cancer (SU2C) Canada Dream Team
The Canadian Cancer Trials Group is very proud to be part of the newly-funded Stand Up to Cancer Canada / Canadian Breast Cancer Foundation Dream Team led by Drs. Tak Mak from the Princess Margaret Cancer Centre and Sam Aparacio from the British Columbia Cancer Agency.

Read more ....

'

Office of Compliance and Oversight

Use of Positron Emitting Radiopharmaceuticals
As sponsor, Canadian Cancer Trials Group has a NEW process to ensure that Canadian Member Centres are using Positron Emitting Radiopharmaceuticals (PER) manufactured in Canada, as per Health Canada requirements.

Read more ....

'

Trial Management Group

Trial Activations -- IND.226 Launches!
Canadian Cancer Trials Group IND.226 -- A Phase IB Study of Durvalumab (MEDI4736) With or Without Tremelimumab in Patients With Advanced Incurable Solid Malignancies Receiving Standard Chemotherapy Regimens -- was centrally activated on October 1, 2015.

Read more ....

'

Trials Closed to Accrual
Three trials were recently closed to accrual -- Canadian Cancer Trials Group PRC.3 (CALGB 90203), Canadian Cancer Trials Group PR.15, and Canadian Cancer Trials Group IND.209.

Read more ....

'

You are receiving this Bulletin because of your involvement with the Canadian Cancer Trials Group. If you no longer wish to receive Canadian Cancer Trials Group Bulletins, please send an unsubscribe request by clicking here.

If you have any questions, comments or suggestions, please contact Canadian Cancer Trials Group Bulletin


Canadian Cancer Trials Group Bulletin

Canadian Cancer Trials Group

Canadian Cancer Trials Group Bulletin

25 Sep 2015

General

Dr. Chris O'Callaghan Promoted to Professor
We are very pleased to announce that Dr. Chris O'Callaghan, Senior Investigator at Canadian Cancer Trials Group's Central Operations and Statistics Office, has been promoted to Professor, Department of Public Health Sciences at Queen's University.

Read more ....

'

Trial Closed to Accrual
Canadian Cancer Trials Group CEC.1 / ECOG 26053_22054 / RTOG 0834 trial - A Phase III Trial on Concurrent and Adjuvant Temozolomide Chemotherapy in Non-1p/19q Deleted Anaplastic Glioma - was recently closed to accrual.

Read more ....

'

Recent Publication
There was one recent publication reporting results of a sub-study included in Canadian Cancer Trials Group REC.2 / ECOG E2805 investigating the effects of adjuvant sorafenib and sunitinib on patients' cardiac function.

Read more ....

'

Group Administrators Office

Welcome Dr. Francisco (Paco) Vera-Badillo
We are very pleased to announce the arrival of Dr. Francisco (Paco) Vera-Badillo to the Canadian Cancer Trials Group's Central Operations and Statistics Centre. Dr. Vera-Badillo is the CTG's newest senior investigator who officially joined us as of September 25, 2015.

Read more ....

'

Welcome to Dr. Greg Korpanty
We are very pleased to let you know that Dr. Greg Korpanty has recently joined the Canadian Cancer Trials Group's Central Operations and Statistics Office as a senior fellow. Over the coming months, Dr. Korpanty will transition to his role as Canadian Cancer Trials Group Senior Investigator.

Read more ....

'

Do You Have News You Would Like To Share?
We are always interested in spreading good news and while we are able to do some sleuthing on our own, we encourage all of our members to let us know about any news and events at your centre that you'd like to share.

Read more ....

'

You are receiving this Bulletin because of your involvement with the Canadian Cancer Trials Group. If you no longer wish to receive Canadian Cancer Trials Group Bulletins, please send an unsubscribe request by clicking here.

If you have any questions, comments or suggestions, please contact Canadian Cancer Trials Group Bulletin


Canadian Cancer Trials Group Bulletin

Canadian Cancer Trials Group

Canadian Cancer Trials Group Bulletin

24 Sep 2015

General

Dr. Chris O'Callaghan Promoted to Professor
We are very pleased to announce that Dr. Chris O'Callaghan, Senior Investigator at Canadian Cancer Trials Group's Central Operations and Statistics Office, has been promoted to Professor, Department of Public Health Sciences at Queen's University.

Read more ....

'

Trial Closed to Accrual
Canadian Cancer Trials Group CEC.1 / ECOG 26053_22054 / RTOG 0834 trial - A Phase III Trial on Concurrent and Adjuvant Temozolomide Chemotherapy in Non-1p/19q Deleted Anaplastic Glioma - was recently closed to accrual.

Read more ....

'

Recent Publication
There was one recent publication reporting results of a sub-study included in Canadian Cancer Trials Group REC.2 / ECOG E2805 investigating the effects of adjuvant sorafenib and sunitinib on patients' cardiac function.

Read more ....

'

Group Administrators Office

Welcome Dr. Francisco (Paco) Vera-Badillo
We are very pleased to announce the arrival of Dr. Francisco (Paco) Vera-Badillo to the Canadian Cancer Trials Group's Central Operations and Statistics Centre. Dr. Vera-Badillo is the CTG's newest senior investigator who officially joined us as of September 25, 2015.

Read more ....

'

Welcome to Dr. Greg Korpanty
We are very pleased to let you know that Dr. Greg Korpanty has recently joined the Canadian Cancer Trials Group's Central Operations and Statistics Office as a senior fellow. Over the coming months, Dr. Korpanty will transition to his role as Canadian Cancer Trials Group Senior Investigator.

Read more ....

'

Do You Have News You Would Like To Share?
We are always interested in spreading good news and while we are able to do some sleuthing on our own, we encourage all of our members to let us know about any news and events at your centre that you'd like to share.

Read more ....

'

You are receiving this Bulletin because of your involvement with the Canadian Cancer Trials Group. If you no longer wish to receive Canadian Cancer Trials Group Bulletins, please send an unsubscribe request by clicking here.

If you have any questions, comments or suggestions, please contact Canadian Cancer Trials Group Bulletin


Canadian Cancer Trials Group Bulletin

Canadian Cancer Trials Group

Canadian Cancer Trials Group Bulletin

11 Sep 2015

General

Recent Publications
There are a number of recent publications, including the primary results of Canadian Cancer Trials Group MA.20 published in the New England Journal of Medicine, a quality of life analysis of Canadian Cancer Trials Group OV.16, and the final report for Canadian Cancer Trials Group PR.3.

Read more ....

'

Group Administrators Office

Dr. Elizabeth Eisenhauer Named to Royal Society of Canada
Dr. Elizabeth Eisenhauer, past Director of the Investigational New Drug Program and past Interim Director of the Canadian Cancer Trials Group, has been named to the Royal Society of Canada.

Read more ....

'

Trial Management Group

Trial Activation
Canadian Cancer Trials Group IND.221 - A Dose-Ranging Study of IPH2201 in Patients with High Grade Serous Carcinoma of Ovarian, Fallopian Tube or Peritoneal Origin - was centrally August 24, 2015.

Read more ....

'

You are receiving this Bulletin because of your involvement with the Canadian Cancer Trials Group. If you no longer wish to receive Canadian Cancer Trials Group Bulletins, please send an unsubscribe request by clicking here.

If you have any questions, comments or suggestions, please contact Canadian Cancer Trials Group Bulletin


Canadian Cancer Trials Group Bulletin

Canadian Cancer Trials Group

Canadian Cancer Trials Group Bulletin

14 Aug 2015

General

Dr. Laurence Klotz Awarded O. Harold Warwick Prize
Dr. Laurence Klotz from Sunnybrook Health Sciences Centre in Toronto was the recipient of the O. Harold Warwick Prize, given to a scientist whose research has had a major impact on cancer control in Canada.

Read more ....

'

Canadian Cancer Trials Group Central Office Holiday Closure
The Canadian Cancer Trials Group Central Operations and Statistics Office will be closed on Monday, September 7, 2015 for Labour Day. Regular business hours will resume on Tuesday, September 8 at 8:30 am EDT.

Read more ....

'

Canadian Cancer Clinical Trials Network
The Canadian Cancer Clinical Trials Network (3CTN) Coordinating Centre has published its inaugural Annual Report!

Read more ....

'

Initiative to Streamline Clinical Trials Workshop
A workshop discussing the Initiative to Streamline Clinical Trials report will be held during the Canadian Cancer Research Alliance Conference on November 10, 2015 in Montreal.

Read more ....

'

Office of Compliance and Oversight

Canadian Food and Drug Regulations Division 5 Training
Effective September 1, 2015, Canadian Food and Drug Regulations Act, Part C, Division 5 Training is mandatory for all participants added to any trial Participants List.

Read more ....

'

Trial Management Group

Trial Activations
Four trials, two led by the Canadian Cancer Trials Group, were recently centrally activated -- SC.24, HE.1, MA.36 (BIG 6-13) and SRC.7 (Alliance 091105).

Read more ....

'

Trials Closed to Accrual
Two trials were recently closed to accrual -- Canadian Cancer Trials Group IND.211 and Canadian Cancer Trials Group MAC.14 (E2108).

Read more ....

'

You are receiving this Bulletin because of your involvement with the Canadian Cancer Trials Group. If you no longer wish to receive Canadian Cancer Trials Group Bulletins, please send an unsubscribe request by clicking here.

If you have any questions, comments or suggestions, please contact Canadian Cancer Trials Group Bulletin


Canadian Cancer Trials Group Bulletin

Canadian Cancer Trials Group

Canadian Cancer Trials Group Bulletin

17 Jul 2015

General

Recent Publications
There were three recent publications -- one reporting primary results of Canadian Cancer Trials Group IND.195, another related to Canadian Cancer Trials Group MA.5 and MA.12, and a third reporting quality of life outcomes from Canadian Cancer Trials Group PR.3 (MRC PR07).

Read more ....

'

Dr. Mary Gospodarowicz Appointed to the Order of Canada
On behalf of the entire Canadian Cancer Trials Group network, congratulations to Dr. Mary Gospodarowicz for being named an Officer of the Order of Canada.

Read more ....

'

Canadian Cancer Trials Group IND.214 In the News
Canadian Cancer Trials Group IND.214 - A Phase I/II Study of MG1 Maraba/MAGE-A3, With and Without Adenovirus Vaccine, With Transgenic MAGE-A3 Insertion in Patients with Incurable Advanced/Metastatic MAGE-A3-Expressing Solid Tumours - was the subject of a recent press event.

Read more ....

'

Central Operations and Statistics Office Holiday Closure
The Canadian Cancer Trials Group Central Operations and Statistics office will be closed on Monday, August 3, 2015 for the Civic Holiday. Regular business hours will resume on Tuesday, August 4 at 8:30 am EDT.

Read more ....

'

Trial Management Group

Trials Closed to Accrual
Canadian Cancer Trials Group IND.208 was recently closed to accrual. In addition, the HD randomization of Canadian Cancer Trials Group PR.13 (MRC PR.10) and an ancillary sub-study of Canadian Cancer Trials Group MAC.12 (ECOG ACRIN PACCT-1) were also closed to further accrual.

Read more ....

'

Trial Activation
We are very pleased to inform you that Canadian Cancer Trials Group MEC.4 (Alliance A091201) - A Randomized Phase II Study Comparing the MET Inhibitor Cabozantinib to Temozolomide / Dacarbazine in Ocular Melanoma - has been centrally activated.

Read more ....

'

Study Acknowledgment/Disclosure Page
Effective July 29, 2015, the Study Acknowledgement/Disclosure Page must now be received prior to a Qualified Investigator becoming active on a trial Participants List.

Read more ....

'

You are receiving this Bulletin because of your involvement with the Canadian Cancer Trials Group. If you no longer wish to receive Canadian Cancer Trials Group Bulletins, please send an unsubscribe request by clicking here.

If you have any questions, comments or suggestions, please contact Canadian Cancer Trials Group Bulletin


Canadian Cancer Trials Group Bulletin

Canadian Cancer Trials Group

Canadian Cancer Trials Group Bulletin

19 Jun 2015

Group Administrators Office

Single-Study Centres and DSMC Summary Reports
Trial-specific DSMC Summary Reports are now posted on trial websites. Single-study centres participating on these trials should download these reports and submit them to their Research Ethics Boards if required by local policy.

Read more ....

'

Canadian Cancer Society Relay for Life
We are extremely grateful to all of the generous donors who contributed to the Canadian Cancer Trials Group Trialblazers participating in this year's Kingston Relay for Life.

Read more ....

'

Canadian Cancer Trials Group Central Office Holiday Closure
The Canadian Cancer Trials Group Central Operations and Statistics Office will be closed on Wednesday, July 1, 2015 for Canada Day. Regular business hours will resume on Thursday, July 2 at 8:30 am EDT.

Read more ....

'

Office of Compliance and Oversight

Canadian Food and Drug Regulations, Division 5
Any participants who have not yet completed the Canadian Food and Drug Act Part C, Division 5 training will begin to receive reminders on July 1, 2015.

Read more ....

'

Trial Management Group

Trial Closed to Accrual
Canadian Cancer Trials Group OV.21 was recently closed to accrual after reaching its accrual target.

Read more ....

'

Trial Activation
Canadian Cancer Trials Group IND.218 -- A Study of Vinblastine and Temsirolimus in Pediatric Patients with Recurrent or Refractory Lymphoma or Solid Tumours Including CNS Tumours -- was centrally activated on June 2.

Read more ....

'

CRA Volunteer Needed for CRA Executive Committee!
The Clinical Research Associates (CRA) Executive Committee is actively seeking a CRA representative for the Canadian Cancer Trials Group CRA Executive Committee. The CRA member is funded to attend the Annual Spring Meeting of Participants.

Read more ....

'

You are receiving this Bulletin because of your involvement with the Canadian Cancer Trials Group. If you no longer wish to receive Canadian Cancer Trials Group Bulletins, please send an unsubscribe request by clicking here.

If you have any questions, comments or suggestions, please contact Canadian Cancer Trials Group Bulletin


Canadian Cancer Trials Group Bulletin

Canadian Cancer Trials Group

Canadian Cancer Trials Group Bulletin

22 May 2015

General

Recent Publications
There have been a number of recent publications, including the primary publications for Canadian Cancer Trials Group MA.31 and SC.20U. Other publications relate to Canadian Cancer Trials Group CO.17, HD.7 (ECOG E2496), LY.12, MA.21 and BR.10.

Read more ....

'

Group Administrators Office

New Investigator Clinical Trials Course
Space for the New Investigator Clinical Trials Course is limited, so send in your application NOW if you are interested in participating.

Read more ....

'

Office of the Director

CCS Relay for Life -- NCIC CTC Trialblazers
Relay for Life is CCS's largest funding raising event. This year, the Central Office has formed a team, The Trialblazers, to participate in the Relay for Life in Kingston on June 6 2015. Support of the Trialblazers, and the CCS, would be appreciated!!

Read more ....

'

Trial Management Group

Trial Activation
Canadian Cancer Trials Group LY.17 - A Multi-stage Randomized Phase II Study of Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma - was centrally activated on May 5, 2015.

Read more ....

'

New EDC Report - Patient Scheduler
A report that generates a list of Electronic Data Capture (EDC) folders by patient, both submitted and expected, is now accessible to sites.

Read more ....

'

Trial Closed to Accrual
Canadian Cancer Trials Group HEC.1 (CALGB 80802) - Phase III Randomized Study of Sorafenib Plus Doxorubicin Versus Sorafenib in Patients with Advanced Hepatocellular Carcinoma - was closed to new patient accrual on May 21, 2015.

Read more ....

'

You are receiving this Bulletin because of your involvement with the Canadian Cancer Trials Group. If you no longer wish to receive Canadian Cancer Trials Group Bulletins, please send an unsubscribe request by clicking here.

If you have any questions, comments or suggestions, please contact Canadian Cancer Trials Group Bulletin


Canadian Cancer Trials Group Bulletin

Canadian Cancer Trials Group

Canadian Cancer Trials Group Bulletin

24 Apr 2015

Group Administrators Office

Spring Meeting Information
The Canadian Cancer Trials Group 2015 Annual Spring Meeting of Participants is being held May 1-3 at the Chelsea Hotel in Toronto. The Spring Meeting Reports for all applicable Phase III, Intergroup trials and IND trials are also now posted on our website.

Read more ....

'

Canadian Cancer Trials Group and Opportunities for Collaboration in Asia
Dr. Lesley Seymour and Alison Urton recently presented at the International Conference on Biostatistics and Bioinformatics for Drug Development.

Read more ....

'

Spring Meeting Friday Highlights
As Spring Meeting approaches, we wanted to highlight some of the special activities that will be taking place on Friday, May 1 from 4:30-6:00 pm, including A Plenary Session, Canadian Cancer Trials Group Recognition Awards Ceremony, and "Libation and Conversation" Reception.

Read more ....

'

Spring Meeting Saturday Highlights
We are very pleased to let you know the General Meeting and the Cosbie Lecture are planned for Saturday, May 2 from 4:30-6:30 pm during Spring Meeting. This year's Cosbie Lecturer is Dr. Joseph Connors.

Read more ....

'

Office of Compliance and Oversight

Reminder: Canadian Food and Drug Regulations, Division 5
Just a quick reminder that the Canadian Cancer Trials Group Division 5 Training Program is now available. This was previously communicated in the Canadian Cancer Trials Group Bulletin on February 13 and 26, 2015.

Read more ....

'

New Harmonized Consent Template
Through continued collaboration with OCREB, the BCCA Research Ethics Board, and Clinical Trials Ontario (CTO), consensus has been reached to produce version 2 of the harmonized informed consent form.

Read more ....

'

New Quebec Research Ethics Board Process - Update
Canadian Cancer Trials Group has established the Quebec Members' Utility which will facilitate communication between our Quebec member sites in the context of the MSSS Framework to authorize research conducted at more than one site.

Read more ....

'

You are receiving this Bulletin because of your involvement with the Canadian Cancer Trials Group. If you no longer wish to receive Canadian Cancer Trials Group Bulletins, please send an unsubscribe request by clicking here.

If you have any questions, comments or suggestions, please contact Canadian Cancer Trials Group Bulletin


Canadian Cancer Trials Group Bulletin

Canadian Cancer Trials Group

Canadian Cancer Trials Group Bulletin

10 Apr 2015

General

A Cancer Research Breakthrough
A Queen's University researcher, in collaboration with two Canadian Cancer Trials Group members, Dr. Anne-Marie Mes-Masson and Dr. Jeremy Squire, has discovered a biomarker that will help lead to better predictions of the success of chemotherapy in ovarian cancer patients.

Read more ....

'

Recent Publications
There were two recent publications -- one describing the effect of metformin vs placebo on weight and metabolic factors in Canadian Cancer Trials Group MA.32 and the other reporting primary results for Canadian Cancer Trials Group IND.204.

Read more ....

'

Launch of NEW Canadian Cancer Trials Group Website
The Canadian Cancer Trials Group's Website Committee is very pleased to inform you that the Canadian Cancer Trials Group's website has been redesigned!! The launch of this new website will take place on Friday, April 17!!!

Read more ....

'

Group Administrators Office

Canadian Cancer Trials Group Recognition Awards
We are pleased to let you know the recipients of this year's Canadian Cancer Trials Group Recognition Awards. These awards will be presented at the Plenary and Recognition Awards ceremony at Spring Meeting.

Read more ....

'

New Investigator Clinical Trials Course
The 2015 New Investigator Clinical Trials Course marks the fifth biennial year of the Course, which was founded in 2007. The next Course is scheduled for August 12-14, 2015 at the Donald Gordon Centre in Kingston. Applications are now being accepted.

Read more ....

'

Spring Meeting Friday Highlights
As Spring Meeting approaches, we wanted to highlight some of the special activities that will be taking place on Friday, May 1 from 4:30-6:00 pm, including A Plenary Session, Canadian Cancer Trials Group Recognition Awards Ceremony, and "Libation and Conversation" Reception.

Read more ....

'

General Information for Spring Meeting Participants
In addition to highlighting Spring Meeting events on Friday and Saturday, we wanted to provide all Spring Meeting Participants with some general information about registration, wireless internet, and Spring Meeting Trial Reports.

Read more ....

'

Spring Meeting Saturday Highlights
We are very pleased to let you know the General Meeting and the Cosbie Lecture are planned for Saturday, May 2 from 4:30-6:30 pm during Spring Meeting. This year's Cosbie Lecturer is Dr. Joseph Connors.

Read more ....

'

Office of the Director

Canadian Cancer Trials Group Marketing and Communication Strategy
In response to recommendations resulting from an Organizational Review conducted at the Canadian Cancer Trials Group Central Operations and Statistics Office in Fall 2014, we are developing a marketing and communications strategy.

Read more ....

'

You are receiving this Bulletin because of your involvement with the Canadian Cancer Trials Group. If you no longer wish to receive Canadian Cancer Trials Group Bulletins, please send an unsubscribe request by clicking here.

If you have any questions, comments or suggestions, please contact Canadian Cancer Trials Group Bulletin


Canadian Cancer Trials Group Bulletin

Canadian Cancer Trials Group

Canadian Cancer Trials Group Bulletin

09 Apr 2015

General

A Cancer Research Breakthrough
A Queen's University researcher, in collaboration with two Canadian Cancer Trials Group members, Dr. Anne-Marie Mes-Masson and Dr. Jeremy Squire, has discovered a biomarker that will help lead to better predictions of the success of chemotherapy in ovarian cancer patients.

Read more ....

'

Recent Publications
There were two recent publications -- one describing the effect of metformin vs placebo on weight and metabolic factors in Canadian Cancer Trials Group MA.32 and the other reporting primary results for Canadian Cancer Trials Group IND.204.

Read more ....

'

Group Administrators Office

Launch of NEW Canadian Cancer Trials Group Website
The Canadian Cancer Trials Group's Website Committee is very pleased to inform you that the Canadian Cancer Trials Group's website has been redesigned!! The launch of this new website will take place on Friday, April 17!!!

Read more ....

'

Canadian Cancer Trials Group Recognition Awards
We are pleased to let you know the recipients of this year's Canadian Cancer Trials Group Recognition Awards. These awards will be presented at the Plenary and Recognition Awards ceremony at Spring Meeting.

Read more ....

'

New Investigator Clinical Trials Course
The 2015 New Investigator Clinical Trials Course marks the fifth biennial year of the Course, which was founded in 2007. The next Course is scheduled for August 12-14, 2015 at the Donald Gordon Centre in Kingston. Applications are now being accepted.

Read more ....

'

Spring Meeting Friday Highlights
As Spring Meeting approaches, we wanted to highlight some of the special activities that will be taking place on Friday, May 1 from 4:30-6:00 pm, including A Plenary Session, Canadian Cancer Trials Group Recognition Awards Ceremony, and "Libation and Conversation" Reception.

Read more ....

'

General Information for Spring Meeting Participants
In addition to highlighting Spring Meeting events on Friday and Saturday, we wanted to provide all Spring Meeting Participants with some general information about registration, wireless internet, and Spring Meeting Trial Reports.

Read more ....

'

Spring Meeting Saturday Highlights
We are very pleased to let you know the General Meeting and the Cosbie Lecture are planned for Saturday, May 2 from 4:30-6:30 pm during Spring Meeting. This year's Cosbie Lecturer is Dr. Joseph Connors.

Read more ....

'

Office of the Director

Canadian Cancer Trials Group Marketing and Communication Strategy
In response to recommendations resulting from an Organizational Review conducted at the Canadian Cancer Trials Group Central Operations and Statistics Office in Fall 2014, we are developing a marketing and communications strategy.

Read more ....

'

You are receiving this Bulletin because of your involvement with the Canadian Cancer Trials Group. If you no longer wish to receive Canadian Cancer Trials Group Bulletins, please send an unsubscribe request by clicking here.

If you have any questions, comments or suggestions, please contact Canadian Cancer Trials Group Bulletin


Canadian Cancer Trials Group Bulletin

Canadian Cancer Trials Group

Canadian Cancer Trials Group Bulletin

27 Mar 2015

General

Recent Publications
There were three recent publications all reporting primary results -- Canadian Cancer Trials Group MA.26 (SWOG 9927), Canadian Cancer Trials Group MAC.11 (SWOG 0221) and Canadian Cancer Trials Group MAC.8 (NSABP B37).

Read more ....

'

Group Administrators Office

Spring Meeting 2015 -- Cosbie Lecture
We are very pleased to announce Dr. Joseph Connors as the 2015 "Cosbie Lecturer." The title of Dr. Connors's talk is "Yin and Yang: Population-Based Studies and Clinical Trials - Lessons from Lymphoid Cancer."

Read more ....

'

Canadian Cancer Trials Group Operations and Statistics Office Holiday Closure
The Canadian Cancer Trials Group Central Operations and Statistics Office will be closed on Friday, April 3, 2015 in observance of Good Friday. Regular business hours will resume on Monday, April 6 at 8:30 am EDT.

Read more ....

'

Trial Management Group

Trial Activations
Two trials were recently activated -- MA.32D (Alliance 21120) and Canadian Cancer Trials Group CLC.2E -- both companion studies.

Read more ....

'

You are receiving this Bulletin because of your involvement with the Canadian Cancer Trials Group. If you no longer wish to receive Canadian Cancer Trials Group Bulletins, please send an unsubscribe request by clicking here.

If you have any questions, comments or suggestions, please contact Canadian Cancer Trials Group Bulletin


Canadian Cancer Trials Group Bulletin

Canadian Cancer Trials Group

Canadian Cancer Trials Group Bulletin

13 Mar 2015

General

Canadian Cancer Trials Group IND.221 Presented at TAT
Dr. Lesley Seymour, Investigational New Drug (IND) Program Director, recently presented the planned IND.221 trial at the Targeted Anticancer Therapies (TAT) Conference in Paris. This phase I trial is investigating IPH2201, a first-in-class NKG2A checkpoint inhibitor.

Read more ....

'

Group Administrators Office

UPDATE -- Canadian Cancer Trials Group Young Investigator Awards
We are pleased to announce that the Young Investigator Awards criteria has been updated. Because of this update, the deadline for nominations for the Ralph Meyer and Elizabeth Eisenhauer Young Investigator Awards has been extended to March 27, 2015.

Read more ....

'

2015 Annual Spring Meeting of Participants
The Canadian Cancer Trials Group 2015 Annual Spring Meeting of Participants will be held May 1-3, 2015 at The Chelsea Hotel in Toronto. The draft Overall Schedule is posted and Registration is open.

Read more ....

'

Trial Management Group

Permanent Trial Closure
Four Intergroup-led trials that included Canadian Cancer Trials Group participation have now been permanently closed -- Canadian Cancer Trials Group OV.13 (EORTC 55971), Canadian Cancer Trials Group OV.19 (MRC ICON 7), Canadian Cancer Trials Group PRC.2 (CALGB 90203) and Canadian Cancer Trials Group AL.4 (DFCI 10-175).

Read more ....

'

You are receiving this Bulletin because of your involvement with the Canadian Cancer Trials Group. If you no longer wish to receive Canadian Cancer Trials Group Bulletins, please send an unsubscribe request by clicking here.

If you have any questions, comments or suggestions, please contact Canadian Cancer Trials Group Bulletin


Canadian Cancer Trials Group Bulletin

Canadian Cancer Trials Group

Canadian Cancer Trials Group Bulletin

27 Feb 2015

Group Administrators Office

2015 Annual Spring Meeting
The Canadian Cancer Trials Group 2015 Annual Spring Meeting of Participants will be held May 1-3, 2015 at the Chelsea Hotel in Toronto.

Read more ....

'

Looking for Volunteers for the Lay Representatives Committee
The Canadian Cancer Trials Group is looking to recruit patients, caregivers and others affected by cancer to join the Canadian Cancer Trials Group (Canadian Cancer Trials Group) Lay Representatives Committee and Disease Site Committees.

Read more ....

'

CORRECTION - Recent Publications in Previous Bulletin
Apologies - in the last Bulletin, Recent Publications were incorrectly identified - trials were IND.177 (not IND.217) and the correct title for IND.200 is "Phase II Study of SB939 in Patients with Translocation-Associated Recurrent/Metastatic Sarcomas."

Read more ....

'

Office of Compliance and Oversight

Reminder: Health Canada Division 5 and GCP V2
Just a quick reminder that the NEW Health Canada Division 5 Training Program and updated GCP Training Program will be implemented March 2, 2015. This was previously communicated in the Canadian Cancer Trials Group Bulletin on February 13, 2015.

Read more ....

'

You are receiving this Bulletin because of your involvement with the Canadian Cancer Trials Group. If you no longer wish to receive Canadian Cancer Trials Group Bulletins, please send an unsubscribe request by clicking here.

If you have any questions, comments or suggestions, please contact Canadian Cancer Trials Group Bulletin


Canadian Cancer Trials Group Bulletin

Canadian Cancer Trials Group

Canadian Cancer Trials Group Bulletin

15 Feb 2015

Group Administrators Office

Central Operations and Statistics Office - Family Day
The Canadian Cancer Trials Group Central Operations and Statistics Office will be closed on Monday, February 16, 2015 to celebrate Family Day. Regular business hours will resume on Tuesday, February 17 at 8:30 am EST.

Read more ....

'

Recent Publications
There were two recent publications both reporting primary results -- Canadian Cancer Trials Group IND.217 and Canadian Cancer Trials Group IND.200.

Read more ....

'

Canadian Cancer Trials Group Recognition Awards
TIME IS RUNNING OUT - Nominations for the Ralph Meyer Phase III Young Investigator, Joseph Pater Excellence in Clinical Trials Research (aka Founder's Award) and the Elizabeth Eisenhauer Early Drug Development Young Investigator Awards are due February 20!

Read more ....

'

2015 Annual Spring Meeting
Funded invitations to the Canadian Cancer Trials Group 2015 Annual Spring Meeting of Participants will be held May 1-3, 2015 at the Chelsea Hotel in Toronto have now been sent.

Read more ....

'

Dr. Laura Dawson Awarded CCSRI QoL Grant
We are very pleased to inform you that Dr. Laura Dawson, radiation oncologist at Princess Margaret, has been awarded a CCSRI Quality of Life Grant for her study looking at palliative radiotherapy for symptomatic hepatocellular carcinoma and liver mets.

Read more ....

'

Office of Compliance and Oversight

GCP Training Program Updated + Other Training Requirements
The Canadian Cancer Trials Group web-based GCP training program (GCP V1) has been updated and will be implemented March 2, 2015 (GCP V2). Please click "read more" to review this update and to read more about other Canadian Cancer Trials Group training updates.

Read more ....

'

New Quebec Research Ethics Board Process
The Quebec Ministry of Health and Social Services, in collaboration with the 4 provincial university health networks, has determined that research projects conducted at more than one institution will undergo a SINGLE ethics review.

Read more ....

'

Revised Investigator Credentialing Policy
The Investigator Credentialing Policy and Delegation Reference Document has been revised so that QIs may delegate the task of approving the delegation of trial-related duties to an appropriately-qualified Participant List Delegate.

Read more ....

'

Trial Management Group

Trials Closed to Accrual
There were two trials recently closed to accrual -- Canadian Cancer Trials Group IND.210 and Canadian Cancer Trials Group IND.206.

Read more ....

'

2015 Permanent Trial Closure
The Canadian Cancer Trials Group's Trial Management Group has completed its annual Permanent Trial Closure assessment. Effective immediately, data submission and REB approval for 12 Canadian Cancer Trials Group-led trials are no longer required.

Read more ....

'

Trial Activations
We are very pleased to inform you that three trials have recently been activated -- Canadian Cancer Trials Group CLC.2 (Alliance A041202), Canadian Cancer Trials Group IND.219 and Canadian Cancer Trials Group PR.17 (ANZUP 1304).

Read more ....

'

You are receiving this Bulletin because of your involvement with the Canadian Cancer Trials Group. If you no longer wish to receive Canadian Cancer Trials Group Bulletins, please send an unsubscribe request by clicking here.

If you have any questions, comments or suggestions, please contact Canadian Cancer Trials Group Bulletin


Canadian Cancer Trials Group Bulletin

Canadian Cancer Trials Group

Canadian Cancer Trials Group Bulletin

30 Jan 2015

Group Administrators Office

Canadian Cancer Trials Group Awarded Infrastructure Funding from CFI
We are very excited to inform you that the Canadian Cancer Trials Group has been awarded $3.8 million through the Canada Foundation for Innovation's Major Science Initiatives.

Read more ....

'

Dr. Andrew Maksymiuk Recognized by CTEP
Dr. Andrew Maksymiuk has been awarded the Joan K. Mauer Memorial Quality Assurance Award by the US Cancer Therapy Evaluation Program.

Read more ....

'

2015 Annual Spring Meeting of Participants
The Canadian Cancer Trials Group 2015 Annual Spring Meeting of Participants will be held May 1-3, 2015 at the Chelsea Hotel, Toronto. UPDATE - Invitations will be sent the week of February 2, 2015.

Read more ....

'

Looking for Volunteers for the Lay Representatives Committee
We are looking to recruit patients, caregivers and others affected by cancer to join the Canadian Cancer Trials Group Lay Representatives Committee and Disease Site Committees. If you know of someone, please click on "read more"!!

Read more ....

'

Trial Management Group

Trial Activation
We are pleased to inform you that IND.216 - A Phase II Study of Buparlisib in Patients with Relapsed and Refractory Chronic Lymphocytic Leukemia - has been centrally activated.

Read more ....

'

You are receiving this Bulletin because of your involvement with the Canadian Cancer Trials Group. If you no longer wish to receive Canadian Cancer Trials Group Bulletins, please send an unsubscribe request by clicking here.

If you have any questions, comments or suggestions, please contact Canadian Cancer Trials Group Bulletin


Canadian Cancer Trials Group Bulletin

Canadian Cancer Trials Group

Canadian Cancer Trials Group Bulletin

16 Jan 2015

General

Recent Publications
There were three recent publications -- the primary publication for Canadian Cancer Trials Group BL.8 (EORTC 30994), the primary publication for Canadian Cancer Trials Group IND.192, and one related to Canadian Cancer Trials Group MA.21.

Read more ....

'

Group Administrators Office

Canadian Cancer Trials Group Annual Spring Meeting of Participants
The Canadian Cancer Trials Group 2015 Annual Spring Meeting of Participants will be held May 1-3, 2015 at the Eaton Chelsea Hotel, Toronto.

Read more ....

'

Canadian Cancer Trials Group Recognition Awards
Canadian Cancer Trials Group's Central Operations and Statistics Office is seeking nominations for the 2015 Canadian Cancer Trials Group Recognition Awards. Deadline for nominations is February 20, 2015.

Read more ....

'

Office of Compliance and Oversight

Changes to Tri-Council Policy Statement
Tri-Council Policy Statement: Ethical Conduct for Research Involving Humans (TCPS 2) has recently been updated. Among the changes is an increased emphasis on the participant's decision-making capacity.

Read more ....

'

Trial Management Group

New Canadian Cancer Trials Group Per Case Funding Sheet
Canadian Cancer Trials Group's Central Operations and Statistics Office is adopting a new template for provision of per case funding information to participating sites. Once in place, funding information will no longer be provided in other study documents.

Read more ....

'

Trials Closed to Accrual
Canadian Cancer Trials Group MDC.1 (S1117) and CEC.2 (NCCTG 0577) have recently been closed to accrual.

Read more ....

'

You are receiving this Bulletin because of your involvement with the Canadian Cancer Trials Group. If you no longer wish to receive Canadian Cancer Trials Group Bulletins, please send an unsubscribe request by clicking here.

If you have any questions, comments or suggestions, please contact Canadian Cancer Trials Group Bulletin


Canadian Cancer Trials Group Bulletins